Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Monoclonal antibody or fragment thereof
Reexamination Certificate
2001-10-18
2004-09-21
Andres, Janet (Department: 1646)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Monoclonal antibody or fragment thereof
C424S139100, C424S085200, C530S351000, C530S388100, C530S389100, C530S388220
Reexamination Certificate
active
06793919
ABSTRACT:
BACKGROUND OF THE INVENTION
1. Field of the Invention
The invention pertains to methods for treating certain diseases and disorders associated with inflammatory and immunoregulatory responses. More particularly, the present invention involves treating rheumatoid arthritis by administering an IL-17 inhibitor or IL-17 antagonist, in particular IL-17 receptor, to an individual afflicted with such rheumatoid arthritis.
2. Description of Related Art
Cytokines are hormone-like molecules that regulate various aspects of an immune or inflammatory response. Cytokines exert their effects by specifically binding receptors present on cells, and transducing a signal to the cells. Rouvier et al. (
J. Immunol.
150:5445; 1993) reported a novel cDNA which they termed CTLA-8; cloning of the human homolog led to the identification of this family of molecules as Interleukin-17 (IL-17; Yao et al.,
Immunity
3:811; 1995). IL-17 is a cytokine produced by activated T cells that stimulates the secretion of various proinflammatory molecules, including tumor necrosis factor &agr; (TNF-&agr;), Interleukin-1 &bgr; (IL-1&bgr;) and prostaglandin E
2
(PGE
2
) from macrophages (Jovanovic et al.,
J. Immunol.
160:3513; 1998).
TNF-&agr; and IL-1 are believed to play a role in the inflammation and bone destruction that occurs in rheumatoid arthritis (RA), albeit through different mechanisms (Joosten et al.,
J. Immunol.
163:5049; 1999). Moreover, elevated levels of IL-17 have been reported to occur in the synovial fluid of RA patients, and may play a role in the bone destruction characteristic of RA (Chabaud et al.,
Arthritis Rheum.
42:963, 1999; Jovanovic et al.,
Arthritis Rheum.
43:1134, 2000).
IL-17 acts on cells by binding to a specific receptor, IL-17R, which was isolated as described U.S. Pat. No. 6,072,033, issued Jun. 6, 2000. IL-17R is present on numerous cell types, including synoviocytes and monocytes/macrophages. Although there are numerous agents known in the art that are used in the treatment of RA, there is a need to identify additional molecules that can be used to treat or ameliorate the symptoms of this chronic inflammatory disease.
SUMMARY OF THE INVENTION
The present invention relates to a method of treating a mammal afflicted with a condition that relates to an inflammatory response, in particular, rheumatoid arthritis, by administering an IL-17 antagonist that inhibits IL-17 mediated signaling to a cell via membrane-bound IL-17 receptor. Suitable IL-17 antagonists include soluble IL-17 receptor, antagonistic antibodies that specifically bind IL-17, antagonistic antibodies to IL-17 receptor and combinations thereof.
Provided herein are methods for treating medical disorders associated with IL-17 mediated inflammatory reactions or IL-17 mediated immunoregulatory reactions. The methods of the present invention include administering an IL-17 antagonist, or IL-1 inhibitor, that inhibits IL-17 inflammatory or immunoregulatory signaling, to an individual afflicted with an inflammatory or immunoregulatory disease mediated by IL-17. More particularly, the present invention involves administering an IL-17 antagonist such as IL-17 receptor, to an individual inflicted with rheumatoid arthritis, for a period of time sufficient to induce a sustained improvement in the patient's condition.
REFERENCES:
patent: 5869286 (1999-02-01), Yao et al.
patent: 6072033 (2000-06-01), Yao et al.
patent: 6072037 (2000-06-01), Yao et al.
patent: 6083906 (2000-07-01), Troutt
patent: 6096305 (2000-08-01), Yao et al.
patent: 6100235 (2000-08-01), Yao et al.
patent: 6191104 (2001-02-01), Spriggs et al.
patent: 6197525 (2001-03-01), Yao et al.
patent: 6680057 (2004-01-01), Yao et al.
patent: WO 95/18826 (1995-07-01), None
patent: WO 96/29408 (1996-09-01), None
patent: WO 97/04097 (1997-02-01), None
patent: WO 98/23284 (1998-06-01), None
patent: WO 99/14240 (1999-03-01), None
patent: WO 99/60127 (1999-11-01), None
patent: WO 00/15759 (2000-03-01), None
patent: WO 00/55204 (2000-09-01), None
patent: WO 01/68705 (2001-09-01), None
patent: WO 01/68859 (2001-09-01), None
Chabaued, M. et al. Arthritis and Rheumatism, 1999, vol. 42, No. 5, pp. 963-970.*
Arend, W. et al. Arthritis and Rheumatism, 1995, vol. 38, No. 2, pp. 151-160.*
Aarvak et al., “Analysis of IL-17 and other cytokines and surface markers of RA inflammatory T cell clones,”American College of Rheumatology(ACR) meeting, Poster 1448, Nov. 1997.
Amin, A. R. et al., “The expression and regulation of nitric oxide synthase in human osteoarthritis-affected chondrocytes: Evidence for up-regulated neuronal nitric oxide synthase,”J. Exp. Med., 182:2097-2102, Dec. 1995.
Antonysamy, M. et al., “Evidence for a of role IL-17 in organ allograft rejection: IL-17 promotes the functional differentiation of dendritic cell progenitors,”J. Immunol., 162:577-584, 1999.
Attur, M. G. et al., “Interleukin-17 up-regulation of nitric oxide production in human osteoarthritis cartilage,”Arthritis&Rheumatism, 40(6):1050-1053, 1997.
Baragi, V. M. et al., “Transplantation of transduced chondrocytes protects articular cartilage from interleukin 1-induced extracellular matrix degradation,”J. Clin. Invest., 96(5):2454-2460, 1995.
Caron, J. P. et al., “Chondroprotective effect of intraarticular injections of interleukin-1 receptor antagonist in experimental osteoarthritis,”Arthritis&Rheum., 39(9):1535-1544, 1996.
Chabaud, M. et al., “Regulation of the effects of IL 17 on IL 6 and LIF production by RA synoviocytes,”American College of Rheumatology(ACR) meeting, Poster 1449, Nov. 1997.
Chabaud, M. et al., “Human Interluekin-17: A T Cell-Derived Proinflammatory Cytokine Produced by the Rheumatoid Synovium,”Arthritis & Rheumatism, 42(5):963-970, 1999.
Chabaud, M. et al., “Contribution of interleukin 17 to synovium matrix destruction in rheumatoid arthritis,”Cytokine, 12(7):1092-1099, 2000.
Chabaud, M. et al., “Enhancing effect of IL-17 on IL-1-Induced IL-6 and leukemia inhibitory factor production by rheumatoid arthritis synoviocytes and its regulation by TH2 cytokines,”J. Immunol., 161:409-414, 1998.
Dudler et al., “In vivo effects of murine recombinant interleukiN-17 on synovial joint in mice,”American College of Rheumatology(ACR) meeting, Poster 1450, Nov. 1997.
Fossiez et al., “T cell interleukin-17 induces stromal cells to produce proinflammatory and hematopoietic cytokines,”J. Exp. Med., 183:2593-2603, 1996.
Fouilhoux et al., “Production of IL-17 and its regulation in rheumatoid synovium,”American College of Rheumatology(ACR)meeting, Poster 1447, 1997.
Joosten et al., “IL-1&agr;&bgr; blockade prevents cartilage and bone destruction in murine type II collagen-induced arthritis, whereas TNF-&agr; blockade only ameliorates joint inflammation,”J. Immunol., 163:5049-5055, 1999.
Jovanovic et al., “Stimulation of 92-kd gelatinase (matrix metalloproteinase 9) production by interleukin-17 in human monocyte/macrophages,”Arthritis Rheum., 43(5):1134-1144, 2000.
Jovanovic, D. et al., “IL-17 stimulates the production and expression of proinflammatory cytokines, IL-&bgr; and TNF-&agr;, by human macrophages,”J. of Immunol., 160:3513-3521, 1998.
Jovanovic, D. et al., “IL-17 stimulates the secretion of proinflammatory cytokines by human macrphages,”American College of Rheumatology(ACR) meeting, Poster 1446, Nov. 1997.
Kotake, S., “IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis,”J. Clin. Invest., 103(9):1345-1352, 1999.
Lotz et al., IL-17 promotes cartilage degradation,Arthritis and Rheumatism, 39 supp.(9):S120, No. 559, 1996.
Spriggs, M. K., “Interleukin-17 and its receptor,”J. Clin. Immunol., 17(5):366-369, 1997.
Yao, Z. et al., “Molecular characterization of the human inteleukin (IL)-17 receptor,”Cytokine, 9(11):794-800, 1997.
Yao et al., “Herpesvirus saimiri encodes a new cytokine, IL-17, which binds to a novel cytokine receptor,”Immunity 3:811-821, 1995.
Yao et al., “Complete nucleotide sequence of the mouseCTLA8gene,”Gene, 168:223-225 1996.
Yao et al., “Human IL-17: A novel cytokine derived from T cells,”J. Immunol., 1555483-5486, 1995
Andres Janet
Henry Janis E.
Immunex Corporation
Klaniecki James E.
LandOfFree
Methods for treating rheumatoid arthritis using IL-17... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for treating rheumatoid arthritis using IL-17..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for treating rheumatoid arthritis using IL-17... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3268748